Sanofi buys into Google's biotech future, pairing up in diabetes

Sanofi is lending its weight to Google's ambitions in life sciences, joining the tech giant's recently unleashed healthcare division in hopes of developing new technologies to help manage diabetes.

Intercept wins priority review for OCA

The FDA granted Intercept's obeticholic acid (OCA) application for primary biliary cirrhosis a priority review, setting the PDUFA date at February 29, 2016.

Bayer takes its heart-failure drug into Phase III after a mid-stage success

Bayer is pushing forward with a new heart-failure treatment that could eventually contend with Novartis' blockbuster-in-waiting Entresto, mapping out a wide Phase III program for its oral drug.

Bristol-Myers forges $1.25B deal to beef up fibrosis pipeline in Promedior buyout

Bristol-Myers Squibb has landed the rights to buy out Lexington, MA-based Promedior, paying $150 million upfront and committing a total of $1.25 billion to the deal--if the biotech's fibrosis drug comes through in Phase II studies.

Step 3: After an immunotherapy makeover, CytomX files $100M IPO

After remaking its pipeline to fit one of the hottest fashions in biotech and engineering a classic $70 million crossover round, South San Francisco-based CytomX is taking the inevitable next step with a $100 million IPO filing.

Amicus bags PhIII rare disease drug in $847M Scioderm buyout

Amicus Therapeutics has stepped in to snap up the late-stage rare disease biotech Scioderm, beefing up its orphan drug pipeline in exchange for $229 million in stock and cash along with a promise of up to $618 million more for meeting a slate of milestones.

Alnylam, Medicines Co. say next-gen PCSK9 drug has blockbuster potential

Now that Amgen and the Regeneron/Sanofi team have scored pioneering approvals of two leading PCSK9 therapies, the race is already on to top the leaders with a new wave of even better drugs that can slash levels of bad cholesterol more efficiently. And Alnylam, alongside its partners at The Medicines Company, has staked out a claim to an RNAi treatment that could beat them all--some 5 years down the road.

Buzz: Ariad soars on reports that Baxalta has come calling about a buyout

Shire has been quiet since making its unwelcomed $30 billion bid to acquire Baxalta public earlier this month. But Baxalta evidently isn't waiting for the next step to play out in that dance. Bloomberg is reporting this afternoon that Baxalta is hunting for an acquisition around the $2 billion mark that would add to its hematology pipeline.

Stem cell researcher cleared of misconduct after U-turn

A stem cell researcher who was accused by colleagues of making up data has been cleared of scientific misconduct. The decision is a boost for Dr. Paolo Macchiarini, a stem cell researcher who went from being featured on the front page of the New York Times to fending off accusations of misconduct.

Intarcia vs. Novo: Which has the most appealing diabetes PhIII program?

Now that Intarcia has come out ahead of Merck's Januvia in the latest study of its implanted extended-release option ITCA-650, some analysts are wondering how the next wrinkle in the big diabetes drug competition will play out.

The FDA offers a controversial solution to the biosimilars name game

The industry has been wrestling for years now over naming the first wave of biosimilars building on the coast of the American drug industry. The FDA's suggested solution: Take the generic name and add four random letters to make it a unique identifier.

Novo Nordisk buys diabetes startups founded by Lilly R&D veteran

Novo Nordisk has gone on a shopping spree in Indiana, picking up a pair of biotechs co-founded by Eli Lilly R&D veteran Richard DiMarchi. The startups, the oldest of which was founded in 2013, are both developing protein-based diabetes drugs based on research performed by DiMarchi.

Eli Lilly's marginal cancer drug becomes Exhibit A in pricing debate

There are a lot of reasons why oncologists aren't exactly brimming with excitement at the idea of getting their hands on Eli Lilly's lung cancer drug necitumumab.

AstraZeneca picks Genentech vet Bohen as its next CMO

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry.

UPDATED: Amgen gets a big win with FDA OK for PCSK9 cholesterol drug Repatha

Amgen scored the big win for its PCSK9 drug Repatha (evolocumab). The FDA announced Thursday afternoon that it has given Amgen a green light on marketing the PCSK9 cholesterol drug, opening the door to what will likely prove a blockbuster market.

Struggling GSK inks a translational deal with QB3

San Francisco incubator QB3 is linking up with pharma giant GlaxoSmithKline on some translational work, looking to push a few academic research projects toward the clinic.

Syndax adds Genentech PD-L1 'atezo' combo pact to its growing pipeline

Genentech has agreed to lend its closely-watched checkpoint inhibitor atezolizumab to Syndax for a combo study with the Waltham, MA-based biotech's lead drug entinostat for triple-negative breast cancer, just three days after Syndax landed an $80 million crossover round.

Kelly Martin takes CEO post; TiGenix up on PhIII cell therapy success; MorphoSys inks I-O deal

Welcome to the latest edition of our weekly EuroBiotech Report. Kelly Martin is back in the hotseat at a biopharma business. Malin, the life science fund Martin helped to set up, gave the former Elan...

Repatha OK looming, analysts wait to see if Amgen will start PCSK9 price war

Amgen is likely to start today off with a case of bubbly chilling in the company cafeteria. The FDA has reached its deadline on a marketing decision for the cholesterol drug Repatha (evolocumab), which most likely is on the verge of becoming a major rival to the newly approved Praluent (alirocumab), from Regeneron and Sanofi.

Ablynx keeps mits on PhIII asset in bid to step up commercial business

Ablynx has decided to retain full ownership in the U.S. and Europe of its Phase III-ready drug for the orphan blood disease acquired thrombotic thrombocytopenic purpura (TTP). A Phase III trial of caplacizumab is due to start soon, setting Ablynx on a path it expects to lead to a filing for conditional approval in Europe early in 2017.